Published by on August 22, 2021
Categories: Travel

Accordingly, we designed the ASTEROID trial (A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived Coronary. The purpose of this study is to see if 40 mg of rosuvastatin taken daily will reduce . statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound- Derived Coronary Atheroma Burden – ASTEROID. Mar 13, Share via: AddThis.

Author: Goltigrel Zulkitaxe
Country: Mozambique
Language: English (Spanish)
Genre: Business
Published (Last): 15 March 2009
Pages: 422
PDF File Size: 6.90 Mb
ePub File Size: 3.15 Mb
ISBN: 735-4-57712-663-1
Downloads: 23305
Price: Free* [*Free Regsitration Required]
Uploader: Daibar

A second imputation method assigned the 22 patients who discontinued the study because of ischemic events to a progression rate calculated from rosuvwstatin median value for all patients completing the trial who showed progression. Sign in to make a comment Sign in to your personal account.

The ASTEROID trial: coronary plaque regression with high-dose statin therapy.

Back to top Article Information. Clinical trials of combination therapies designed to both lower LDL-C and raise HDL-C using novel antiatherosclerotic therapies are currently under way and will report results within the next 18 months.

Early statin treatment in patients with acute coronary syndrome: Manual planimetry was used to trace the leading edges of the luminal and external elastic membrane EEM borders. Regression of coronary atherosclerosis by simvastatin: Thirty-three patients did not have a final IVUS result analyzed, 13 of whom did not undergo a final IVUS examination and 20 of whom had IVUS results that were not analyzable because of artifacts or pullbacks shorter than the prespecified mm grial length.


Two primary efficacy parameters were prespecified: Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: N Engl J Med. Administrative, technical, or material support: Purchase access Subscribe now.

Unfortunately, the goal of inducing actual regression of atherosclerosis has remained elusive. This change represents a median reduction of 6. To assess whether very intensive statin therapy could regress coronary atherosclerosis as determined by IVUS imaging. Two patients experienced serious adverse events based on local, non—study-related laboratory values. The baseline and follow-up pullbacks were reviewed as a pair. The magnitude and consistency of regression observed in the current trial are noteworthy.

Get free access to newly published articles Create a personal account or sign in to: One approach imputed all noncompleting patients as showing no change in atheroma burden neither progression nor regression.

Raichlen, MD ; Christie M. The observed increases in HDL-C in the current study suggest that therapies designed to simultaneously lower LDL-C while raising HDL-C have the potential to substantially reduce lesion burden in patients aeteroid established disease.

The ASTEROID trial: coronary plaque regression with high-dose statin therapy.

A motorized pullback was repeated under asterood identical to the baseline study. All measurements were performed at the end of the study, after both the baseline and follow-up IVUS examinations were available.

In parallel to clinical outcomes trials, imaging studies have examined the effects of antiatherosclerotic therapies on the progression of atherosclerosis.


Using this more conservative end point, only a small study of patients administered an intravenous HDL-C mimetic apolipoprotein A-1 Milano phospholipid has previously shown regression. We compensated for the absence of placebo controls by blinding date information on IVUS studies and resequencing the examinations to eliminate observer bias in interpretation.

Sign in to customize your interests Sign in to your personal account. These changes were larger in magnitude than has been observed in previous statin trials.

After a month treatment period, actively participating patients underwent repeat IVUS examination. The institutional review boards of all participating centers approved the protocol and all patients provided written informed consent. Purchase access Subscribe to the journal. A secondary efficacy variable, change in normalized total atheroma volume for the entire artery, was also prespecified. Figure 2 shows a representative cross-section at baseline and follow-up for a patient who exhibited marked regression of disease.

The sponsor was permitted to review the manuscript and suggest changes, but the final decision on content asreroid exclusively retained by the authors. He has consulted for a number of pharmaceutical companies without financial compensation. Change in total atheroma volume showed a 6.